Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel Tremblay

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
British Journal of Cancer|April 9, 2020
Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treatment of unresectable hepatocellular carcinomaAndrew Briggs, Bruno Daniele, Katherine Dick, et al.
Future Oncology (London, England)|March 2, 2022
Effectiveness of crizotinib versus entrectinib in <i>ROS1</i>-positive non-small-cell lung cancer using clinical and real-world dataGabriel Tremblay, Michael Groff, Laura Iadeluca, et al.
Patient Preference and Adherence|November 26, 2015
Health state utility valuation in radioactive iodine-refractory differentiated thyroid cancerBeth A Fordham, Cicely Kerr, Hayley M de Freitas, et al.
Journal of Medical Internet Research|August 1, 2023
Economic Evaluation Associated With Clinical-Grade Mobile App-Based Digital Therapeutic Interventions: Systematic ReviewYoann Sapanel, Xavier Tadeo, Connor T A Brenna, et al.
BMC Cancer|April 29, 2024
Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myelomaMeletios Dimopoulos, Pieter Sonneveld, Salomon Manier, et al.
Journal of Medical Economics|July 22, 2024
Population health outcomes of blood-based screening for colorectal cancer in comparison to current screening modalities: insights from a discrete-event simulation model incorporating longitudinal adherenceShaun P Forbes, Elifnur Yay Donderici, Nicole Zhang, et al.
Pharmacoeconomics|July 2, 2024
Cost-Effectiveness of Plasma Microbial Cell-Free DNA Sequencing When Added to Usual Care Diagnostic Testing for Immunocompromised Host PneumoniaAndrew J Sutton, Daniel S Lupu, Stephen P Bergin, et al.
JAMA Network Open|July 12, 2022
Economic Evaluation of Cost and Time Required for a Platform Trial vs Conventional TrialsJay J H Park, Behnam Sharif, Ofir Harari, et al.
Frontiers in Pain Research (Lausanne, Switzerland)|February 16, 2026
Barriers and facilitators to implementing immersive virtual reality in long-term care settings: an interdisciplinary partnership study exploring staff perspectivesIsabel Sadowski, Mael Gagnon-Mailhot, Gbeada Josiane Seu, et al.
Future Oncology (London, England)|February 2, 2021
Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphomaJatin Shah, Sharon Shacham, Michael Kauffman, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
British Journal of Cancer|April 9, 2020
Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treatment of unresectable hepatocellular carcinomaAndrew Briggs, Bruno Daniele, Katherine Dick, et al.
Future Oncology (London, England)|March 2, 2022
Effectiveness of crizotinib versus entrectinib in <i>ROS1</i>-positive non-small-cell lung cancer using clinical and real-world dataGabriel Tremblay, Michael Groff, Laura Iadeluca, et al.
Patient Preference and Adherence|November 26, 2015
Health state utility valuation in radioactive iodine-refractory differentiated thyroid cancerBeth A Fordham, Cicely Kerr, Hayley M de Freitas, et al.
Journal of Medical Internet Research|August 1, 2023
Economic Evaluation Associated With Clinical-Grade Mobile App-Based Digital Therapeutic Interventions: Systematic ReviewYoann Sapanel, Xavier Tadeo, Connor T A Brenna, et al.
BMC Cancer|April 29, 2024
Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myelomaMeletios Dimopoulos, Pieter Sonneveld, Salomon Manier, et al.
Journal of Medical Economics|July 22, 2024
Population health outcomes of blood-based screening for colorectal cancer in comparison to current screening modalities: insights from a discrete-event simulation model incorporating longitudinal adherenceShaun P Forbes, Elifnur Yay Donderici, Nicole Zhang, et al.
Pharmacoeconomics|July 2, 2024
Cost-Effectiveness of Plasma Microbial Cell-Free DNA Sequencing When Added to Usual Care Diagnostic Testing for Immunocompromised Host PneumoniaAndrew J Sutton, Daniel S Lupu, Stephen P Bergin, et al.
JAMA Network Open|July 12, 2022
Economic Evaluation of Cost and Time Required for a Platform Trial vs Conventional TrialsJay J H Park, Behnam Sharif, Ofir Harari, et al.
Frontiers in Pain Research (Lausanne, Switzerland)|February 16, 2026
Barriers and facilitators to implementing immersive virtual reality in long-term care settings: an interdisciplinary partnership study exploring staff perspectivesIsabel Sadowski, Mael Gagnon-Mailhot, Gbeada Josiane Seu, et al.
Future Oncology (London, England)|February 2, 2021
Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphomaJatin Shah, Sharon Shacham, Michael Kauffman, et al.
Pageof 6